

Monitoring and mitigating shortages of medicines and management of public health emergencies/major events

23-24 April 2024 The Supply of Plasma-Derived Medicinal Products in the Future of Europe





Disclaimer

These PowerPoint slides are copyright of the European Medicines Agency. Reproduction is permitted provided the source is acknowledged.

The presenter does not have any conflict of interests.



Monitoring and mitigating **shortages of medicines** and management of public health emergencies/major events



Regulation (EU) 2022/123

- > Provides a framework for activities established by the European Medicines Agency to monitor and mitigate potential and actual shortages of medicines
- > Sets processes/tools for shortages reporting and coordinates responses of EU countries to shortages of critical medicines (during a crisis) and for monitoring of events, including medicine shortages, which might lead to a crisis situation (public health emergencies or major events)
- ➤ Establishes "Medicines Shortages Steering Group" (MSSG) supported by the SPOC Working Party and a Network of contact points from pharmaceutical companies (i-SPOCs)
- > Foresees the development of the **European Shortages Monitoring Platform** (ESMP) by Feb 2025



KEY BENEFIT

More coordination in preventing and mitigating medicines shortages in the EU

Availability of medicines: EU level coordination





Crisis and preparedness (PHEs, MEs)



Normal Circumstances



Executive Steering

Group on Shortages

and Safety of

medicinal products

EMA extended mandate



EC Pharma Strategy



EMANS 2025





(MSSG) Executive group

- Opinion on a major event
- · List of critical medicines
- Monitoring of shortages, supply and demand in PHE/ME
- Recommendations to MS, industry and EC



Medicine Shortages SPOC Working Party

Operational group

- Monitoring critical shortages and events that could lead to a major event or public health emergency and reporting these to the MSSG (war in Ukraine, antibiotics, thrombolytics)
- Drawing up lists of critical medicines during a major event and during a public-health emergency at the request of MSSG



EMA/HMA Task Force on availability of authorized medicinal products

(TF AAM)

Policy group

- Supply and availability hub
- · Structural and strategic solutions
- Development of guidance and policy



Joint Action on Shortages

MSSG recent initiatives





Solidarity mechanism

- Voluntary mechanism
- Help from one another in obtaining medicines during critical shortages
- Last resort
- 5 conditions to be met
- Pilot



Toolkit of recommendations


- Monitoring of demand and supply
- European and international cooperation
- Increased supply and fair distribution
- Regulatory flexibilities
- Communication

MSSG Solidarity mechanism process (europa.eu)

MSSG recommendations toolkit (europa.eu)

Preparedness activities: interactions with stakeholders







Union list of Critical Medicines

Objectives & scope

1. Ensuring medicines considered most critical for health systems are always available.

2. Provide industrial capacity/ support where medicines' supply chain vulnerabilities and dependencies are identified.

3. Enable
Short- to
Medium^{1*} and
long-term^{2*}
Supply
Security
measures

- 1. Suppliers' diversification or increase production within the EU,
- 2. Investment incentives,
- 3. Additional regulatory obligations for companies,
- 4. Procurement with strong contractual obligations for delivery.

https://ec.europa.eu/commission/presscorner/detail/en/ip_23_5190



Methodology: criteria

Categorization of medicines in three groups

Critical medicines

Medicines at risk

Other medicines

Risk classification based on two criteria (with three risk levels each)



Criterion 1

Therapeutic indication High, medium, low risk



Criterion 2

Availability of alternatives High, medium, low risk




Categorization according to a risk matrix





Union list of critical medicines - Immunoglobulins



- The current list reflects the outcome of the review of 600 active substances and combinations of active substances from existing national lists of critical medicines.
- It will be updated and extended in 2024 after the review of medicines that are not included in those national lists.
- Availability of critical medicines

Conclusion and next steps

- EMA continues to monitor shortages of immunoglobulins through the SPOC WP
- EMA will continue to facilitate regular dialogue with MAHs to obtain a detailed overview of the availability of immunoglobulins and to discuss potential support measures to prevent or mitigate shortages in the EU/EEA.
- The union list of critical medicines to be a living document, subject to continuous review and potential update.
- The list is contributing to the EC's exercise to analyse the supply chain of critical medicines to determine potential vulnerabilities and identify regulatory measures (MSSG) and/or industrial policy measures (CMA) to address those.



Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on **9 @EMA_News**